Cogent Biosciences, Inc. SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense
Cogent Biosciences, Inc. (COGT) reported SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense of $92.48 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-17.
Financial Statements › Notes › Valuation and Qualifying Accounts
us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense · last filed 2026-02-17
- Cogent Biosciences, Inc. sec schedule, 12-09, valuation allowances and reserves, additions, charge to cost and expense for fiscal 2025 was $92.48M, a 50.41% increase from fiscal 2024.
- Cogent Biosciences, Inc. sec schedule, 12-09, valuation allowances and reserves, additions, charge to cost and expense for fiscal 2024 was $61.48M, a 8.95% decline from fiscal 2023.
- Cogent Biosciences, Inc. sec schedule, 12-09, valuation allowances and reserves, additions, charge to cost and expense for fiscal 2023 was $67.53M, a 57.56% increase from fiscal 2022.
- Cogent Biosciences, Inc. sec schedule, 12-09, valuation allowances and reserves, additions, charge to cost and expense for fiscal 2022 was $42.86M, a 126.90% increase from fiscal 2021.
| Period end | SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense 12 month |
|---|---|
| 2025-12-31 | $92.48M 10-K · filed 2026-02-17 |
| 2024-12-31 | $61.48M 10-K · filed 2026-02-17 |
| 2023-12-31 | $67.53M 10-K · filed 2026-02-17 |
| 2022-12-31 | $42.86M 10-K · filed 2025-02-25 |
| 2021-12-31 | $18.89M 10-K · filed 2024-02-26 |
| 2019-12-31 | $9.59M 10-K · filed 2021-03-16 |
| 2018-12-31 | $12.29M 10-K · filed 2020-03-26 |
| 2017-12-31 | $10.98M 10-K · filed 2019-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |